Market Overview

Ascendiant Capital Initiates Cytori Therapeutics With Buy

Related CYTX
20 Biggest Mid-Day Losers For Tuesday
Benzinga's Top Upgrades, Downgrades For July 25, 2017

Ascendiant Capital initiated coverage on Cytori Therapeutics Inc (NASDAQ: CYTX) with a Buy rating.

The target price for Cytori Therapeutics is set to $1.25.

Cytori Therapeutics shares have dropped 69.00 percent over the past 52 weeks, while the S&P 500 index has surged 10.96 percent in the same period.

Cytori Therapeutics' shares climbed 2.69 percent to $0.730 in after-hours trading.

Latest Ratings for CYTX

Jul 2017B. RileyDowngradesBuyNeutral
Dec 2016B. RileyInitiates Coverage OnBuy
May 2015Ascendiant CapitalInitiates Coverage onBuy

View More Analyst Ratings for CYTX
View the Latest Analyst Ratings

Posted-In: Ascendiant CapitalInitiation Analyst Ratings


Related Articles (CYTX)

View Comments and Join the Discussion!